Evidence map›Paper›PMID 41047464›Full record

ReviewJournal of inherited metabolic disease2025

Revisiting the Genetics of Hypophosphatasia.

Priya S Kishnani, Catherine Rehder, Keiichi Ozono, Jordi Pérez-López, Guillermo Del Angel, William R Mowrey, Meena Balasubramanian, Wolfgang Högler, Eric T Rush

Erratum issuedAbstract readReview
In one paragraph

Review in Journal of inherited metabolic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Revisiting the Genetics of Hypophosphatasia.Journal of inherited metabolic disease · 2025
    Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Priya S KishnaniDuke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0001-8251-909X
Catherine RehderDuke University Medical Center, Durham, North Carolina, USA.
Keiichi OzonoISEIKAI International General Hospital, Osaka, Japan.
Jordi Pérez-LópezGlobal Medical Affairs, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
Guillermo Del AngelCentre for Genomics Research, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA.
William R MowreyBioinformatics and Data Science, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
Meena BalasubramanianDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Wolfgang HöglerDepartment of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.
Eric T RushChildren's Mercy Kansas City, Kansas City, Missouri, USA.

Funding

Alexion, AstraZeneca Rare Disease
6 · The paper itself

Abstract

Hypophosphatasia (HPP) is a rare, inherited monogenic disorder that is typically caused by variants in the tissue-nonspecific alkaline phosphatase (ALPL) gene. Genetic testing for ALPL variant(s) to confirm the diagnosis in patients with suspected HPP is a standard practice based on availability. This review attempts to improve the current understanding of the genetics of HPP as it addresses five key related topics: (1) HPP patterns of inheritance and the relationship between HPP genotype and phenotype, (2) how the disease can manifest (including specific genotypes) in heterozygotes, (3) potential reasons why some patients have persistently low alkaline phosphatase activity yet lack an ALPL variant, (4) the implications of and resources for variants of uncertain significance (VUS), and (5) recent information on genetic testing in fetuses and newborns. We summarize pertinent information applicable in daily clinical practice, with the objective of preventing missed, delayed, or incorrect HPP diagnoses and improving patient care.

Indexed as

Alkaline PhosphataseHypophosphatasiaGenetic TestingGenotypeHumansInfant, NewbornMutationPhenotypeAlkaline PhosphataseALPL protein, humanalkaline phosphatasebone mineralizationdominant‐negative effectgenetic counselinggenetic screeninggenetic testinggenome sequencinggenotypephenotypevitamin B6

Identifiers

PMID41047464
PMCPMC12497681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.